Medline IPO Rumors: Expected Ticker, Valuation, Date & How to Buy Shares

Medline Industries is sprinting toward the public markets with a blockbuster initial public offering that could raise up to $5.37 billion and value the 59-year-old medical-supply giant at roughly $37 billion—making it the largest U.S. IPO of 2025 so far. According to updated SEC filings, the Northfield, Illinois-based company will offer 179 million shares at an expected price range of $26 to $30 under the ticker “MDLN” on the Nasdaq Global Select Market. Cornerstone investors—including Capital Group, Morgan Stanley’s Counterpoint Global, Durable Capital Partners, GIC, Janus Henderson, Viking Global and WCM—have already indicated interest in nearly half the deal, pledging about $2.4 billion, while the founding Mills family plans to buy an additional $250 million of stock. The company’s pedigree is formidable: Medline supplies more than 335,000 products—ranging from surgical gloves and gowns to lab equipment—through 69 distribution centers and a private truck fleet that can reach 95 percent of U.S. hospitals within 24 hours. For the 12 months ended Sept. 30, 2025, Medline generated $27.4 billion in revenue, underscoring the pandemic-driven surge in demand for personal protective equipment and continuing expansion into laboratory, animal-health and international markets. Medline’s IPO is also a private-equity milestone: Blackstone, Carlyle and Hellman & Friedman teamed up to buy a majority stake in 2021, reportedly valuing the business at about $34 billion. A successful listing would unlock liquidity for those backers while giving retail investors their first chance to own a slice of one of America’s largest family-founded healthcare suppliers. Key dates and what to watch • Pricing window: the syndicate—led by Goldman Sachs, Morgan Stanley, BofA, J.P. Morgan and more than 20 additional underwriters—expects to set the final price the week of December 15, 2025. • First trade: shares could debut on the Nasdaq as early as December 16-17, subject to market conditions. • Lock-ups: insiders are generally restricted from selling for 180 days; watch for secondary offerings in mid-2026. SEO tips for prospective investors • Search interest in phrases like “how to buy Medline IPO stock,” “Medline IPO date,” and “Medline IPO valuation” is climbing fast—bookmark your brokerage’s IPO access portal now. • Retail allocations often depend on order-size tiers; submitting indications of interest early can improve allocation odds. • Track the SEC’s EDGAR database for any last-minute amendments that might alter the price range or share count. Bottom line Medline’s debut combines scale, profitability and a healthcare supply chain story that resonates with both growth and value investors. If demand meets expectations, MDLN could breathe new life into a long-quiet U.S. IPO market and set the tone for healthcare flotations in 2026.